文献速递皮肤肿瘤

利特昔替尼联合或不联合窄谱中波紫外线治疗活动性非节段性白癜风的2b期扩展研究

Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study.
PubMed 文献 · J Am Acad Dermatol · 2024-12-19

本研究为2b期扩展研究,评估利特昔替尼联合或不联合窄谱中波紫外线(nbUVB)光疗治疗活动性非节段性白癜风的疗效与耐受性。43例接受联合治疗,187例接受单药治疗。第24周时,联合组面部和全身白斑复色改善更显著,且耐受性良好,无新安全信号。

要点

  • 利特昔替尼联合nbUVB可能提高面部和全身白斑复色疗效
  • 联合治疗耐受性良好,未观察到新的安全信号
  • 研究为探索性分析,样本量小,需谨慎解读

核心结论

  • 利特昔替尼单药及联合nbUVB治疗均可改善面部和全身白斑复色,且耐受性良好;加用nbUVB可能提高利特昔替尼疗效。

研究设计与样本

  • 2b期扩展研究,患者先接受24周安慰剂对照剂量探索期,随后接受利特昔替尼200 mg 4周后50 mg 20周,联合或不联合nbUVB光疗每周2次。
  • 联合组43例,单药组187例。缺失数据采用末次观测值结转和观测病例法处理。

主要发现

  • 联合治疗耐受性良好,未观察到新的安全信号。

临床怎么用

  • 对于活动性非节段性白癜风患者,利特昔替尼联合nbUVB光疗可能作为改善面部和全身复色的治疗选择。

局限性

  • 本研究为探索性分析;停药标准仅适用于联合组;样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ritlecitinib demonstrated efficacy in a phase 2b trial of nonsegmental vitiligo. OBJECTIVE: To evaluate the efficacy and tolerability of ritlecitinib with add-on narrow-band ultraviolet B (nbUVB) phototherapy in patients with nonsegmental vitiligo. METHODS: Following a 24-week, placebo-controlled, dose-ranging period, patients received ritlecitinib 200 mg for 4 weeks then 50 mg for 20 weeks, with or without nbUVB phototherapy 2x/week. Missing data were handled using last observation carried forward and observed case (OC). RESULTS: Forty-three patients received ritlecitinib + nbUVB and 187 received ritlecitinib-monotherapy. Nine patients receiving ritlecitinib + nbUVB discontinued due to nbUVB group-specific efficacy criteria requiring >10% improvement in % change from baseline (% change from baseline) in Total-Vitiligo Area Scoring Index at week 12. At week 24, mean % change from baseline in Facial-VASI score was -57.0 vs -51.5 (last observation carried forward; P = .158) and -69.6 vs -55.1 (OC; P = .009), for ritlecitinib + nbUVB vs ritlecitinib-monotherapy, respectively. Mean % change from baseline in Total-Vitiligo Area Scoring Index at week 24 was -29.4 vs -21.2 (last observation carried forward; P = .043) and -46.8 vs -24.5 (OC; P < .001), respectively. nbUVB addition to ritlecitinib was well tolerated with no new safety signals. LIMITATIONS: Exploratory analysis; discontinuation criterion applied only to the ritlecitinib + nbUVB group; small sample size. CONCLUSION: Ritlecitinib alone and with nbUVB therapy improved facial and total body repigmentation and was well tolerated. Adding nbUVB may improve ritlecitinib efficacy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Yamaguchi Y, Peeva E, Adiri R, et al. Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study. J Am Acad Dermatol. 2024. PMID: 39709084. doi:10.1016/j.jaad.2024.11.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。